Prevalence of Vitamin D Insufficiency in Adult Hematopoietic Cell Transplant (HCT) Patients with Documented Osteopenia or Osteoporosis after Steroid Exposure: A Quality Assurance Study  by Schmidt, Erin M. & McMillen, Kerry K.
Figure 1. Disease status
Abstracts / Biol Blood Marrow Transplant 21 (2015) S266eS321 S299428
Prevalence of Vitamin D Insufﬁciency in Adult
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Background: Steroid exposure is a known risk factor for
osteopenia and osteoporosis. Vitamin D insufﬁciency is a
known factor that contributes to bone loss. Low concentra-
tions of vitamin D are associated with impaired calcium
absorption, negative calcium balance and a compensatory
rise in parathyroid hormone, which results in excessive bone
resorption. Historically at Seattle Cancer Care Alliance, adult
allogeneic HCT patients treated with steroids routinely have
a Dual Energy X-ray Absorptiometry (DEXA) scan at depar-
ture. While many patients were found to have osteopenia or
osteoporosis, it was unknown how many of these patients
were additionally vitamin D deﬁcient.
Objective: The aims of this quality assurance study were: 1)
to identify the prevalence of vitamin D insufﬁciency in adult
HCT patients with osteopenia or osteoporosis post-HCT and
2) to evaluate the need to change standard practice guide-
lines at our center to assess for vitamin D insufﬁciency more
regularly in at-risk groups.
Design: We identiﬁed all allogeneic HCT patients with post-
HCT steroid exposure and documented osteopenia or oste-
oporosis on departure DEXA scan over a six month period. A
serum 25-OH vitamin D level was drawn on patients meeting
these criteria.
Results: 40 adults met inclusion criteria: 22 males and 18
females. All patients were receiving 1500 mg calcium and
800 international units vitamin D3 daily with combination of
diet, multivitamin and/or supplements per standard practice
guidelines at Seattle Cancer Care Alliance. All patients were
counseled by a registered dietitian to ensure adequate cal-
cium and vitamin D intake.
4 patients had deﬁcient 25-OH vitamin D levels (25-OH
vitamin D <20 ng/mL), 25 patients had insufﬁcient levels
(25-OH vitamin D 20-30 ng/mL), 11 patients had normal
vitamin D levels (>30 ng/mL).
The prevalence of insufﬁciency or deﬁciency was 73% (29/
40). Stratiﬁed by age, the prevalence of insufﬁciency or
deﬁciency was:
20-29 years old 8% (3/40)
30-39 years old 10% (4/40)
40-49 years old 20% (8/40)
50-59 years old 15% (6/40)
60 years old 20% (8/40)
Males comprised 50% patients with 25-OH vitamin D
deﬁciency. 65% patients with 25-OH vitamin D insufﬁciency
were males, 35% females.
Conclusion/Applications: 25-OH vitamin D insufﬁciency
and deﬁciency are prevalent in post-HCT patients with
conﬁrmed osteopenia and/or osteoporosis. Vitamin D insuf-
ﬁciency and deﬁciency were prevalent across all ages and
genders highlighting the need to assess vitamin D status in
the total patient population.
Based on these ﬁndings, standard practice was modiﬁed
at Seattle Cancer Care Alliance to include a 25-OH vitamin D
level pre-HCT and at day 80 post-HCT to better identify and
treat 25-OH vitamin D insufﬁciency/deﬁciency.429
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Background: The prognosis of chronic myeloid leukemia
(CML) in advanced stages (accelerated phase or blast crisis) is
still poor even with tyrosine kinase inhibitors (TKIs). Allo-
geneic hematopoietic cell transplantation is the only curative
treatment for them.
Method: Using our database, we retrospectively collected
CML patients transplanted at Toranomon Hospital between
June 2004 and March 2014, after the introduction of TKIs in
Japan.
Result: Twenty-nine consecutive patients were extracted.
The median age was 52 years (range; 16-70). The disease
status at diagnosis was chronic phase (CP, n¼11), accelerated
phase (AP, n¼5) and blast crisis (BC, n¼13). All patients were
treated with TKIs before transplantation including imatinib
(n¼15), nilotinib (n¼1), dasatinib (n¼6), imatinib/dasatinib
(n¼4), nilotinib/dasatinib (n¼1) and imatinib/nilotinib/
dasatinib (n¼2). All of 11 patients in CP at diagnosis pro-
gressed into AP/BC in their course and only 3 patients ach-
ieved second CP at transplantation. On the other hand, 11 of
18 patients in AP/BC at diagnosis achieved CP at trans-
plantation and the remaining 7 patients did not achieve CHR
(Fig.1). The median HCT-CI and EBMT score at trans-
plantationwas 2 (range, 0-5) and 5 (range, 0-7), respectively.
Additional cytogenetic abnormalities developed in 19 of 29
patients until transplantation. Point mutations in ABL gene
were detected in 9 of 20 patients (45%) in their course.
Overall, 14 of 29 (48%) patients underwent transplantation in
CP stage. The donors were related PBSC (n¼6), unrelated BM
